Novo Nordisk’s new fast-acting mealtime insulin for the treatment of diabetes in adults, Fiasp, has been launched in Canada, following the recent marketing authorisation from Health Canada on 6 January 2017.
The company explained that Fiasp is insulin aspart in an innovative formulation that more closely matches the natural physiological insulin response of a person without diabetes after a meal, compared with NovoRapid (conventional insulin aspart). Furthermore, the company said, Fiasp has the option of a flexible dosing regimen (up to 20 minutes after starting a meal), without compromising overall glycaemic control, when compared to NovoRapid dosed at mealtime.
“The launch of Fiasp in Canada represents the first new mealtime insulin in 10 years,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “The goal of any insulin treatment is to match the natural physiological insulin production we see in people without diabetes, both in speed and glycaemic control. Fiasp has narrowed the existing gap, getting us closer to that goal.”